AbbVie Inc. (FRA:4AB0)

Germany flag Germany · Delayed Price · Currency is EUR
18.60
-0.30 (-1.59%)
At close: Feb 20, 2026
Market Cap337.40B +3.7%
Revenue (ttm)52.09B +8.6%
Net Income3.57B -1.2%
EPS2.01 -1.3%
Shares Outn/a
PE Ratio94.64
Forward PE15.44
Dividend0.59 (3.15%)
Ex-Dividend DateJan 16, 2026
Volumen/a
Average Volume1
Open18.70
Previous Close18.90
Day's Range18.60 - 18.70
52-Week Range14.40 - 21.00
Betan/a
RSI49.56
Earnings DateApr 24, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4AB0
Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements